Simulations Plus (NASDAQ:SLP) posted its quarterly earnings data on Wednesday. The technology company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.02, Fidelity Earnings reports. The business had revenue of $8.03 million for the quarter, compared to the consensus estimate of $7.52 million. Simulations Plus had a net margin of 25.27% and a return on equity of 25.23%.
Shares of NASDAQ:SLP traded up $0.23 during trading on Friday, hitting $34.83. 86,800 shares of the company were exchanged, compared to its average volume of 91,130. The firm’s 50 day moving average price is $34.16 and its 200-day moving average price is $31.83. The stock has a market capitalization of $575.56 million, a P/E ratio of 72.56 and a beta of -0.34. Simulations Plus has a 12-month low of $17.18 and a 12-month high of $41.95.
The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 25th were given a dividend of $0.06 per share. The ex-dividend date of this dividend was Thursday, October 24th. This represents a $0.24 annualized dividend and a dividend yield of 0.69%. Simulations Plus’s dividend payout ratio is presently 50.00%.
In other Simulations Plus news, Director Walter S. Woltosz sold 24,000 shares of the stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $35.86, for a total value of $860,640.00. Following the completion of the sale, the director now owns 5,087,918 shares of the company’s stock, valued at $182,452,739.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 72,000 shares of company stock valued at $2,532,720 in the last ninety days. 31.57% of the stock is owned by corporate insiders.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Story: Gross Domestic Product (GDP)
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.